Forest escitalopram
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NDA submitted March 23 for single-isomer version of Forest's Celexa (citalopram) for treatment of depression. The SSRI will receive a standard review. Phase III results will be presented at the American Psychiatric Association meeting May 5-1